Tech Transfer Roundup: J&J Innovation’s Agnostic Approach To Academic Collaboration
J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.
You may also be interested in...
Option to acquire a company developing a CB1-targeted antibody for non-alcoholic steatohepatitis gets Johnson & Johnson into the race. Janssen’s James List explains how the NASH venture fits into J&J’s growing efforts in metabolic disease.
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
Through a series of research agreements, J&J arm is seeking to create new business models teaming a single internal expert with a host of external researchers in six priority therapeutic areas.